KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Bionano Genomics (BNGO) Asset Writedowns and Impairment (2017 - 2024)

Bionano Genomics (BNGO) has disclosed Asset Writedowns and Impairment for 5 consecutive years, with -$6.2 million as the latest value for Q4 2024.

Quarterly Asset Writedowns and Impairment changed N/A to -$6.2 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $1.0 million through Dec 2025, down 28.43% year-over-year, with the annual reading at $1.4 million for FY2024, N/A changed from the prior year.
Asset Writedowns and Impairment hit -$6.2 million in Q4 2024 for Bionano Genomics, down from $7.2 million in the prior quarter.
In the past five years, Asset Writedowns and Impairment ranged from a high of $7.2 million in Q3 2024 to a low of -$6.2 million in Q4 2024.
Historically, Asset Writedowns and Impairment has averaged $268625.0 across 3 years, with a median of $366000.0 in 2020.